Haemonetics (HAE) Proxy filing summary

Executive summary

• The annual meeting is scheduled for July 24, 2026, with shareholders voting on director elections, executive compensation, auditor ratification, and amendments to incentive and stock purchase plans.

• The company reported strong fiscal 2026 performance, meeting or exceeding most financial targets despite headwinds from portfolio transitions and macroeconomic uncertainty.

• Key strategic achievements included FDA clearances for new plasma and vascular closure technologies, acquisition of Vivasure Medical, and leadership team enhancements.

• Shareholder engagement remains a priority, with active outreach and feedback incorporated into governance and compensation decisions.

Voting matters and shareholder proposals

• Shareholders will vote on electing eight directors, approving executive compensation (say-on-pay), ratifying Ernst & Young LLP as auditor, and amending/restating the 2019 Long-Term Incentive Compensation Plan and 2007 Employee Stock Purchase Plan.

• The board recommends voting in favor of all proposals.

Board of directors and corporate governance

• The board consists of nine members (eight standing for election), with an average independent director tenure of 8.4 years and an average age of 68.9.

• All committees are composed solely of independent directors, and the board maintains an independent chair structure.

• Annual board and committee self-evaluations, including peer reviews, are conducted to promote refreshment and effectiveness.

• Shareholders have the right to call special meetings, and majority voting provisions are in place.